Combined loss of e-cadherin and aberrant β-catenin protein expression correlates with a poor prognosis for small intestinal adenocarcinomas

American Journal of Clinical Pathology

Volumn 139, Issue 2, 2013, Pages 167-176

  Lee, Hee Jin ^a   Lee, Ok Jun ^b   Jang, Kee Taek ^c   Bae, Young Kyung ^d   Chung, Joon Yong ^e   Eom, Dae Woon ^a   Kim, Joon Mee ^f   Yu, Eunsil ^a   Hong, Seung Mo ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Chungbuk National University College of Medicine   (South Korea)

^c Sungkyunkwan University   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Inha University School of Medicine   (South Korea)

Author keywords

Adenocarcinoma; B catenin; E cadherin; Immunohistochemistry; Prognosis; Small intestine

Indexed keywords

BETA CATENIN; UVOMORULIN; CADHERIN; CTNNB1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; FEMALE; GASTROINTESTINAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNET RING CARCINOMA; SMALL INTESTINE ADENOCARCINOMA; SMALL INTESTINE CANCER; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR INVASION; ADENOCARCINOMA; COLLOID CARCINOMA; INTESTINE TUMOR; LYMPH NODE; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SMALL INTESTINE; SOUTH KOREA;

ADENOCARCINOMA; ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; BETA CATENIN; CADHERINS; CARCINOMA, SIGNET RING CELL; FEMALE; HUMANS; INTESTINAL NEOPLASMS; INTESTINE, SMALL; LYMPH NODES; MALE; MIDDLE AGED; PROGNOSIS; REPUBLIC OF KOREA; SURVIVAL RATE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84875058621     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPS54RTFCTHGWX     Document Type: Article

References (29)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 2009;19:58-69.
3. Cobrin GM, Pittman RH, Lewis BS. Increased diagnostic yield of small bowel tumors with capsule endoscopy. Cancer. 2006;107:22-27.
4. Chang HK, Yu E, Kim J, et al. Adenocarcinoma of the small intestine: A multi-institutional study of 197 surgically resected cases. Hum Pathol. 2010;41:1087-1096.
5. Sutter T, Arber N, Moss SF, et al. Frequent K-ras mutations in small bowel adenocarcinomas. Dig Dis Sci. 1996;41:115-118.
6. Wheeler JM, Warren BF, Mortensen NJ, et al. An insight into the genetic pathway of adenocarcinoma of the small intestine. Gut. 2002;50:218-223.
7. Arber N, Hibshoosh H, Yasui W, et al. Abnormalities in the expression of cell cycle-related proteins in tumors of the small bowel. Cancer Epidemiol Biomarkers Prev. 1999;8:1101-1105.
8. Blaker H, von Herbay A, Penzel R, et al. Genetics of adenocarcinomas of the small intestine: Frequent deletions at chromosome 18q and mutations of the SMAD4 gene. Oncogene. 2002;21:158-164.
9. Planck M, Ericson K, Piotrowska Z, et al. Microsatellite instability and expression of MLH1 and MSH2 in carcinomas of the small intestine. Cancer. 2003;97:1551-1557.
10. Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2:442-454.
11. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science. 2004;303:1483-1487.
12. Breuhahn K, Singh S, Schirmacher P, et al. Large-scale N-terminal deletions but not point mutations stabilize beta-catenin in small bowel carcinomas, suggesting divergent molecular pathways of small and large intestinal carcinogenesis. J Pathol. 2008;215:300-307.
13. Svrcek M, Jourdan F, Sebbagh N, et al. Immunohistochemical analysis of adenocarcinoma of the small intestine: A tissue microarray study. J Clin Pathol. 2003;56:898-903.
14. Blaker H, Helmchen B, Bonisch A, et al. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas. Scand J Gastroenterol. 2004;39:748-753.
15. Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: A comparison with colorectal adenocarcinoma. Mod Pathol. 2006;19:573-580.
16. Estrella JS, Wu TT, Rashid A, et al. Mucosal colonization by metastatic carcinoma in the gastrointestinal tract: A potential mimic of primary neoplasia. Am J Surg Pathol. 2011;35:563-572.
17. Chung JY, Hong SM, Choi BY, et al. The expression of phospho-AKT, phospho-mTOR, and PTEN in extrahepatic cholangiocarcinoma. Clin Cancer Res. 2009;15:660-667.
18. Koorstra JB, Hong SM, Shi C, et al. Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia. Mod Pathol. 2009;22:1439-1445.
19. Maitra A, Ashfaq R, Gunn CR, et al. Cyclooxygenase 2 expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasia: An immunohistochemical analysis with automated cellular imaging. Am J Clin Pathol. 2002;118:194-201.
20. Hansel DE, Rahman A, Hermans J, et al. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol. 2003;16:652-659.
21. Fiocca R, Luinetti O, Villani L, et al. Molecular mechanisms involved in the pathogenesis of gastric carcinoma: Interactions between genetic alterations, cellular phenotype and cancer histotype. Hepatogastroenterology. 2001;48:1523-1530.
22. Winter JM, Ting AH, Vilardell F, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res. 2008;14:412-418.
23. Hong SM, Li A, Olino K, et al. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Mod Pathol. 2011;24:1237-1247.
24. Murata M, Iwao K, Miyoshi Y, et al. Molecular and biological analysis of carcinoma of the small intestine: Beta-catenin gene mutation by interstitial deletion involving exon 3 and replication error phenotype. Am J Gastroenterol. 2000;95:1576-1580.
25. Park S, Kim SW, Lee BL, et al. Expression of E-cadherin and beta-catenin in the adenoma-carcinoma sequence of ampulla of Vater cancer. Hepatogastroenterology. 2006;53:28-32.
26. Hsu HP, Shan YS, Jin YT, et al. Loss of E-cadherin and beta-catenin is correlated with poor prognosis of ampullary neoplasms. J Surg Oncol. 2010;101:356-362.
27. Ozguven BY, Karacetin D, Kabukcuoglu F, et al. Immunohistochemical study of E-cadherin and beta-catenin expression in colorectal carcinomas. Pol J Pathol. 2011;62:19-24.
28. Matsuoka T, Mitomi H, Fukui N, et al. Cluster analysis of claudin-1 and-4, E-cadherin, and beta-catenin expression in colorectal cancers. J Surg Oncol. 2011;103:674-686.
29. Liu LK, Jiang XY, Zhou XX, et al. Upregulation of vimentin and aberrant expression of E-cadherin/beta-catenin complex in oral squamous cell carcinomas: Correlation with the clinicopathological features and patient outcome. Mod Pathol. 2010;23:213-224.